IL-15 Enhanced NK Cell Therapy for Solid Tumors

Starting soon · Early Phase 1

Conditions studied: Solid Tumors, Metastatic Cancer

In brief

A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.

Key facts

Study ID

NCT07621471

Run by

Genovn Therapeutics (Suzhou) Co., Ltd.

People needed

12

Starts

2026-07-01

Expected to finish

2028-12-31

Last updated by the study team

2026-06-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-70 years;
• ECOG 0-1;
• histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);
• failed prior standard therapy;
• >=1 measurable lesion per RECIST 1.1;
• adequate bone marrow, liver, kidney, and coagulation function;
• recovered from prior treatment toxicities;
• signed informed consent.

You may not qualify if…

• Pregnancy/lactation;
• other malignancy within 5 years (except cured localized tumors);
• active autoimmune disease or immunodeficiency;
• uncontrolled cardiovascular disease or infection;
• active TB;
• positive HBsAg/HBcAb or HCV antibody (unless viral load undetectable);
• positive syphilis antibody;
• major surgery or vaccination within 28 days;
• prior cell therapy;
• severe allergy to study drugs;
• investigator judged unsuitable.

Where it is running

• Xinqiao Hospital — Chongqing, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.